Dr. Reddys Laboratories Ltd.

Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce a novel drug for the prevention of lower respiratory tract disease in newborns. The company plans to introduce Beyfortus, which contains the monoclonal antibody, nirsevimab, in a prefilled injection used for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants. 

The medication is also administered in children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season. RSV is a highly contagious virus that can lead to serious respiratory illness in infants. Under the arrangement, Dr Reddy's will have exclusive rights from Sanofi to promote and distribute Beyfortus in India.

The announcement follows Dr Reddy's successful exclusive distribution partnership with Sanofi for their portfolio of vaccines in India last year. The company is expected to launch Beyfortus in India in the second quarter of the current fiscal year.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.